Sanguine Corporation Announces PHER-O2 MRI Business MOU Signing

PASADENA, CA--(Marketwire - September 29, 2008) - Sanguine Corporation (OTCBB: SGUI) is pleased to announce that the Company has expanded the use of PHER-O2 by signing a Memorandum of Understanding (MOU) with a medical device company to test the product as a potential carrying agent for a patented MRI procedure. Testing to verify the effective use of PHER-O2 as a carrying agent will be paid for by the medical device company. Management recognizes the importance of this opportunity and believes the worldwide marketplace for an MRI diagnostic carrying agent is substantial.